This Week’s Biopharma News: New Approvals, Appeals, and AI
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
False
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
By James Strachan
June 1, 2026
Kelly Broster of Thermo Fisher Scientific explains why GLP-1 peptides are exposing the limits of traditional analytical workflows
12 min read
By Stephanie Harden, Tracy Hibbs
May 29, 2026
Accelerating analytical data management for the next-generation laboratory
7 min read
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
May 22, 2026
A new series championing analytical scientists in pharma begins with Genentech’s rising star
7 min read
By Manuel Möller
May 21, 2026
Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes
5 min read
May 19, 2026
Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.
3 min read
By Malin Karlsson
May 19, 2026
Maximizing insight from limited samples, aligning data across molecular layers, and building consistency from the first step
3 min read
By Robert Balog
May 18, 2026
How advances in microarray technology are helping bring genomic data closer to real-time clinical decision-making
4 min read
May 15, 2026
Meg Carr reflects on the key themes from this year’s show – from contamination control and AI to flexible facility design
3 min read
False
False
False
Affiliations:
Specialties:
Areas of Expertise: